Loading...
Market
What will be the overall survival rate improvement in stage III EGFR+ NSCLC patients treated with Tagrisso by mid-2025?
5
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Clinical trial results and peer-reviewed medical journals
Story
AstraZeneca's Tagrisso Shows Major PFS Benefit (HR=0.16) in Stage III Lung Cancer Laura Trial
Jun 2, 2024, 12:56 PM
At the ASCO 2024 conference, AstraZeneca reported significant findings regarding its drug Tagrisso and its impact on stage III non-small cell lung cancer (NSCLC) with EGFR mutations. The Laura trial demonstrated a massive progression-free survival (PFS) benefit with a hazard ratio of 0.16. However, the study noted an 81% rate of placebo patient crossover, effectively making it a comparison of maintenance Tagrisso versus Tagrisso on progression. Osimertinib could alter the standard of care (SOC) for stage III EGFR+ NSCLC, according to Dr. Ramalingam. These findings highlight the potential of targeted therapies in improving cancer treatment outcomes.
View original story
Similar markets
Less than 20% • 33%
20% to 40% • 33%
Greater than 40% • 34%
Less than 20 • 33%
20 to 40 • 33%
More than 40 • 34%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
Increase by less than 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Progression-Free Survival (PFS) • 33%
Overall Survival (OS) • 33%
Both PFS and OS • 33%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 60% • 25%
60-70% • 25%
70-80% • 25%
More than 80% • 25%